The most meaningful HIV cure will be not only safe and effective but also widely accessible for the 39 million people infected worldwide, no matter who they are or where they live.
Hans-Peter Kiem, MD, PhD, is pursuing such a cure in the form of in vivo gene therapy that confers HIV resistance to a specific subset of a patient’s hematopoietic stem cells, or HSCs, the building blocks of our blood and immune systems. He was awarded $480,000 by amfAR, The Foundation for AIDS Research, to support the next stage of his work.
